New phase 3 data at aasld show durable response to odevixibat in a rare pediatric liver disease

- pedfic 1 meets both u . s . and eu primary and secondary endpoints with high ly statistically significant reductions in serum bile acids and pruritus -

ALBO Ratings Summary

ALBO Quant Ranking